更新于：2024-12-16

Eszopiclone

右佐匹克隆

更新于：2024-12-16

概要

概要

基本信息

药物类型

小分子化药

别名

(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate、(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate、(+)-Zopiclone

+ [17]

靶点

GABAA receptor

作用机制

GABAA receptor正向变构调节剂(γ-氨基丁酸 A 受体正向别构调节剂)

治疗领域

神经系统疾病

在研适应症

入睡和睡眠障碍

非在研适应症

注意缺陷障碍伴多动重度抑郁症广泛性焦虑障碍+ [3]

原研机构

Sumitomo Pharma America, Inc.

在研机构

Eisai Co., Ltd.

江苏天士力帝益药业有限公司Waylis Therapeutics LLC

非在研机构

Sumitomo Pharma America, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2004-12-15),

入睡和睡眠障碍

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C17H17ClN6O3

InChIKeyGBBSUAFBMRNDJC-INIZCTEOSA-N

CAS号138729-47-2

关联

项与右佐匹克隆相关的临床试验

NCT05953610 / Recruiting临床2期IIT

Endotypic Traits and Obstructive Sleep Apnea Surgery

This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).

开始日期2024-01-07

申办/合作机构

University of California, Los Angeles

[+1]

NCT05951023 / Recruiting临床2期IIT

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP): a Pilot Trial

More than 10% of the US population have obstructive sleep apnea (OSA). Standard of care is therapy with CPAP (continuous positive airway pressure) which virtually eliminates OSA. However, most patients use CPAP only for part of the night (4-5hours) and about 50% patients discontinue CPAP long-term. Alternative therapies are limited, thus many OSA patients remain at risk of OSA sequelae (e.g. sleepiness, memory issues, high blood pressure, etc.). Importantly, different patients get OSA for different reasons, and recent data show that some of the underlying causes of OSA ("endotypes") such as having a low arousal threshold (i.e. waking up easily) are associated with lower CPAP adherence. Using a randomized controlled trial design, this will be the first study using a targeted intervention to manipulate the underlying OSA causes (i.e., giving a safe hypnotic to patients with OSA to increase the arousal threshold) to test the hypothesis that endotype-targeted therapy increases CPAP-adherence in patients who have low but continued CPAP usage. Ultimately, this strategy may improve the care and outcomes of millions of undertreated OSA patients.

开始日期2023-08-31

申办/合作机构

University of California San Diego

[+1]

NCT06017921 / Recruiting临床4期IIT

Effect of Eszopiclone on Adherence to Continuous Positive Airway Pressure (CPAP) and Severity of Insomnia in Patients With Comorbidity Between Insomnia and Obstructive Sleep Apnea (COMISA)

The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA only. The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on adherence to CPAP after 30 days and after 6 months.

开始日期2023-08-24

申办/合作机构

University of Sao Paulo General Hospital

100 项与右佐匹克隆相关的临床结果

登录后查看更多信息

100 项与右佐匹克隆相关的转化医学

登录后查看更多信息

100 项与右佐匹克隆相关的专利（医药）

登录后查看更多信息

348

项与右佐匹克隆相关的文献（医药）

2024-11-01·EXPERT OPINION ON PHARMACOTHERAPY

Pharmacological and non-pharmacological management of sleep disturbances in Parkinson’s disease: if when and how

Review

作者: Falup-Pecurariu, Cristian ; Murasan, Iulia ; Ungureanu, Larisa ; Chaudhuri, Kallol Ray ; Diaconu, Stefania ; Popławska-Domaszewicz, Karolina ; Muntean, Maria-Lucia

INTRODUCTION:

Sleep dysfunction occurs in various forms and is a bothersome and intrusive non-motor symptom of Parkinson's disease (PD). Frequently undiagnosed, their poor management can have a great impact on the quality of life of PD patients and their caregivers.

AREAS COVERED:

This article covers the safety and efficacy of pharmacological strategies for the management of the most frequent sleep disturbances in Parkinson's disease. Non-pharmacological aspects are also discussed, but these are not the main focus. Literature searches using electronic databases (Medline, Cochrane Library) and systematic checking of references from review articles/other reports were performed.

EXPERT OPINION:

Melatonin and clonazepam are the most commonly used therapies for the management of REM sleep behavior disorder (RBD). The most used pharmacological wake-promoting agents in the treatment of excessive daytime sleepiness (EDS) are modafinil and caffeine. Poor nocturnal sleep quality is usually linked to EDS, thus proper sleep hygiene is recommended. As nocturnal motor symptoms are commonly associated with sleep fragmentation and early morning off, optimization of dopaminergic treatment during nighttime is highly recommended for the proper management of insomnia. Further interventions include eszopiclone and melatonin for the management of insomnia. Therapeutic options for restless legs syndrome (RLS) include calcium channel alpha-2-delta ligands and low-dose dopamine agonists (DA). Further confirmatory evidence is needed before the general recommendation of these treatments.

2024-11-01·CLINICAL NEUROPHARMACOLOGY

Pharmacological Management of Acute and Chronic Insomnia: A Cross-Sectional Study

Article

作者: Ospina-Sánchez, Santiago ; Sánchez-Ramírez, Nicolás ; Machado-Alba, Jorge Enrique ; Valladales-Restrepo, Luis Fernando ; Usma-Valencia, Andrés Felipe ; Gaviria-Mendoza, Andrés ; Machado-Duque, Manuel

Objective:

Insomnia is a frequent and difficult disease to treat. The objective was to determine the pharmacological management of a group of patients diagnosed with acute and chronic insomnia.

Methods:

This is a cross-sectional study that identified patterns of prescription of drugs for outpatient use in patients with insomnia from a population database of 8.5 million individuals in the Health System of Colombia. Sociodemographic and pharmacological variables were considered.

Results:

A total of 5825 patients with insomnia were identified. Acute insomnia was the most frequent complaint (85.2%). A total of 76.9% received pharmacological treatment, mainly through off-label drugs (70.7%), such as trazodone (20.2%), quetiapine (12.3%), and clonazepam (11.1%). The approved drugs were used in 9.9% of the patients, especially eszopiclone (4.7%) and zopiclone (3.6%). Benzodiazepines and Z compounds predominated in the elderly and individuals with chronic insomnia.

Conclusions:

The pharmacological treatment of insomnia in this group of patients is heterogeneous, and medications not approved for this indication are very frequently used.

2024-11-01·CLINICAL PSYCHOLOGY & PSYCHOTHERAPY

Efficacy of Mindfulness Meditation on Patients With Stroke With Concurrent Coronary Heart Disease: A Randomised Controlled Trial

Article

作者: Kou, Lulu ; Kang, Shaowei ; Ni, Guangxiao ; Liu, Min

ABSTRACT:

Objective:

This study aimed to investigate the efficacy of mindfulness meditation on sleep quality and negative emotions in patients with stroke with concurrent coronary heart disease.

Methods:

This study was a randomised controlled trial. A total of 72 patients with stroke with concurrent coronary heart disease were randomly divided into an observation group and a control group, with 36 patients in each group. The control group received routine treatment plus eszopiclone tablets at a dosage of 3 mg once daily. The observation group received mindfulness meditation in addition to the treatment given to the control group. The Pittsburgh Sleep Quality Index was used to assess sleep status, the Self‐Rating Anxiety Scale and Self‐Rating Depression Scale were used to assess depression and anxiety, and the Fugl–Meyer Assessment was used to assess motor function. All participants in both groups received a 6‐week intervention.

Results:

Pairwise comparisons revealed that the observation group had better outcomes in sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disturbances, daytime function and total scores at both 6 and 12 weeks compared with the control group (p < 0.05). After 12 weeks of intervention, compared with the control group, the total score of sleep quality improved more significantly (9.22 ± 2.35/6.26 ± 2.47). Additionally, different treatment methods had varying effects on anxiety scores, depression scores and motor function scores between the two groups (p < 0.001). Further comparisons showed that the observation group had lower anxiety and depression scores and higher motor function scores at both 6 and 12 weeks compared with the control group (p < 0.05).

Conclusion:

Mindfulness meditation can effectively improve sleep quality and reduce negative emotions in patients with stroke with concurrent coronary heart disease, as well as promote the recovery of limb functions.

项与右佐匹克隆相关的新闻（医药）

2024-08-06

·药通社

重磅新闻！华润斥资62亿，收购天士力！

天士力8月4日下午披露，公司控股股东天士力生物医药产业集团有限公司（下称“天士力集团”）及其一致行动人天津和悦科技等拟向华润三九合计转让其所持有的天士力股份4.18亿股，占公司总股本的28%。与此同时，天士力集团拟向国新投资转让所持有的7469.75万股天士力股份（占比5%）。截至目前，天士力集团及其一致行动人合计持有天士力股票7.54亿元，持股比例为50.5008%。股权转让后，其合计持股下降至2.61亿股，持股比例为17.5008%；华润三九、国新投资的持股比例分别为28%、5%。天士力集团还承诺，股份登记在华润三九名下之日起，其将放弃所持天士力5%股份对应的表决权等，使其控制的表决权比例不超过12.5008%。通过上述交易，华润三九将成为天士力的控股股东，中国华润将成为天士力的实际控制人。并且，据证券时报报道，目前天士力的相关业务与中国华润旗下公司存在同业竞争。华润三九方面承诺，在上述交易完成后五年内解决该同业竞争问题。天士力是A股中药板块龙头之一，产品覆盖中药、化学制剂药、化学原料药、生物药等领域。公司主打产品为复方丹参滴丸等。2023年度，天士力营业收入为86.74亿元，净利润为10.71亿元。今年一季度，公司营业收入为20.49亿元，净利润为2.95亿元。华润三九主要从事医药产品的研发、生产、销售及相关健康服务。公司前身是1985年成立的深圳南方制药厂。1999年，由三九企业集团、深圳三九药业股份有限公司等5家公司发起设立股份制公司。2000年3月9日，公司在深交所上市。2008年，公司正式进入中国华润。华润三九主营核心业务定位于CHC健康消费品和处方药领域。2023年，华润三九拥有年销售额过亿元的品种39个，其中包括“999 感冒灵”“999皮炎平”等。2023年，公司实现营业收入247.39亿元，同比增长36.83%；净利润28.53亿元，同比增长16.50%。 8月4日下午，华润三九也披露了重大资产购买预案。对于收购天士力，华润三九表示，交易有利于公司巩固行业领先地位，提升核心竞争力，通过充分整合双方资源，实现中药产业链的补链强链延链，发挥研发协同价值，符合公司“争做行业头部企业”等企业愿景和发展战略。值得一提的是，天士力的医药零售连锁业务与中国华润下属华润医药的零售连锁业务存在同业竞争，天士力生产的右佐匹克隆片与华润三九生产的佐匹克隆片存在同业竞争。华润三九、中国华润等出具了《关于避免同业竞争的承诺函》，承诺自上述股权交易完成后五年内，按照法定程序通过包括但不限于托管、资产（股权）转让、业务整合等方式解决上述同业竞争问题。据媒体报道，近年来华润三九持续并购多家知名药企。自2008年起，华润三九已成功发起超15次外延式并购。其中，华润三九于2022年12月完成对昆药集团28%股份的收购，并于去年1月正式入主。在2023年年报中，华润三九明确表示，2024年是国民经济趋稳回升的关键之年，也是公司迈向新发展阶段的关键之年。公司将在稳定存量业务基础上，重点发力创新转型，积极开展并购及业务合作，增强可持续增长的核心能力。同时，作为中药产业链龙头企业之一，公司将为提升中药产业竞争力贡献力量。华润，已经成为名副其实的中药一哥——“华润三九，东阿阿胶，江中药业，昆药集团”，如今，再增加一个华润天士力。内容来源于网络，如有侵权，请联系删除。

并购财报

2024-03-23

·药融圈

【药融咨询】掘金中国失眠创新药蓝海，谁领风骚？

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。3月21日是世界睡眠日，人的生命约有1/3是在睡眠中度过的，睡眠与健康密切相关。睡眠障碍已经成为影响全球人类健康的一个突出问题，失眠症是最常见的睡眠障碍，流行病学研究显示，中国有45.4%的被调查者在过去1个月中曾经历过不同程度的失眠。长期失眠影响个体的正常生活和工作，增加罹患各种健康问题的风险。严重的睡眠缺失将降低患者的工作效率和警觉水平，甚至有可能引发恶性意外事故，造成巨大损失。目前催眠镇静剂市场规模超48亿，临床仍有较大的未满足需求失眠的治疗方法主要包括心理治疗和药物治疗。心理治疗是首选的治疗方法，但因难以获得和成本高昂等原因应用不广。药物治疗主要包括苯二氮卓类受体激动剂（benzodiazepine receptor agonists，BZRAs）、褪黑素受体激动剂、食欲素受体拮抗剂和具有催眠效应的抗抑郁药物。据药融云数据显示，2022年失眠化药在全国院内市场销售额超48亿元。目前国内失眠化药多为老品种(地达西尼上市前我国失眠行业近16年没有新药获批)，多家仿制药上市，价格偏低，导致国内市场规模始终保持较低水平。2018-2023年全国院内镇静催眠药物市场规模（数据截至2023Q3）截图来源：药融云全国院内销售数据库BZRAs：分为苯二氮卓类药物和非苯二氮卓类药物。BZDs于20世纪60年代开始使用，可非选择性激动γ-氨基丁酸受体A上不同的α1亚基，具有镇静、催眠、抗焦虑、肌肉松弛和抗惊厥的药理作用。20世纪80年代以来，以唑吡坦（zolpidem）和右佐匹克隆（eszopiclone）为代表的non-BZDs先后应用于失眠的临床治疗，它们对γ-氨基丁酸受体A上的α1亚基选择性激动，主要发挥催眠作用，不良反应较BZDs轻，已经逐步成为治疗失眠的临床常用药物。褪黑素和褪黑素受体激动剂：褪黑素参与调节睡眠觉醒周期，可以改善时差变化所致睡眠觉醒障碍、睡眠觉醒时相延迟障碍等昼夜节律失调性睡眠觉醒障碍，但使用普通褪黑素治疗失眠尚无一致性结论，故不推荐将普通褪黑素作为催眠药物使用。食欲素受体激动剂：食欲素又称下丘脑分泌素，具有促醒作用。针对食欲素双受体发挥抑制作用的拮抗剂苏沃雷生（suvorexant），已获得美国食品药品监督管理局批准用于治疗成人失眠（入睡困难和睡眠维持障碍）。其发挥催眠作用的靶点不同于其他催眠药，现有研究数据显示其具有较好的临床疗效和耐受性。抗抑郁药物：部分抗抑郁药具有镇静作用，在失眠伴随抑郁、焦虑心境时应用较为有效。临床上常用具有镇静催眠作用的药物中国失眠创新药一片蓝海，空间巨大自2007年江苏天士力帝益药业的右佐匹克隆上市以来，中国创新失眠药领域一直面临长期空白，直到2023年浙江京新药业的地达西尼上市后，才打破国内16年来没有治疗失眠障碍创新药上市的局面。2010年以来中国上市失眠创新药Dimdazenil（地达西尼）地达西尼是治疗失眠的1类小分子新药，为为γ-氨基丁酸A型（GABAA）受体的部分正向别构调节剂，通过部分激活GABAA受体，产生促进睡眠的作用。与传统失眠药物相比具有GABAA受体部分激动，避免过度抑制，日间损害和不良反应更小；1h达峰，快速诱导睡眠；半衰期4h，有效维持生理睡眠；主要通过FMO代谢，显著降低药物相互作用风险的特点。截图来源：药融云全球药物研发数据库地达西尼最早由Roche研发，随后德国公司Evotec获得全球独占权并将其开发用于治疗失眠症，于2008年在国外完成I、II期临床。2010年京新药业与Evotec签署协议，获得地达西尼在中国的独家专利许可和开发权。地达西尼在中国的获批上市是基于JX202001-EVT201-III一项评价EVT201胶囊对比安慰剂在失眠障碍患者中疗效和安全性的多中心、随机、双盲III期临床试验。基于统计分析模型，以第13/14晚PSG监测的平均TST值为反应变量，基线TST、年龄为协变量，组别为自变量计算，EVT201胶囊组相对于安慰剂组的优效性成立，EVT201胶囊可快速起效、提高睡眠效率，同时改善次日嗜睡等残留效应。食欲素是一种由下丘脑自然产生的神经肽，食欲素和其受体共同构成的食欲素系统能够刺激唤醒中枢神经系统的目标神经元，然后释放几种促进清醒的化学物质。近年来食欲素及其拮抗剂的研究越来越受到重视，已发现食欲素拮抗剂对失眠具有治疗作用。目前中国在研失眠新药中就是主要以食欲素受体（OX1R、OX2R）为主。中国在研失眠创新药Lemborexant（莱博雷生）Lemborexant是卫材研发的一款双重食欲素拮抗小分子药物，通过竞争性结合OX1R、OX2R，抑制食欲素神经传递，调节睡眠-觉醒节律。双食欲素神经肽信号系统在觉醒中有重要作用，作为一种竞争性拮抗剂，莱博雷生对OX2R具有更强的抑制作用，可抑制REM和非REM睡眠驱动，从而为患者提供更快的睡眠开始、更好的睡眠维持。截图来源：药融云全球药物研发数据库一项为期12个月的全球多中心、随机双盲、平行组的III期临床实验结果显示，莱博雷生与安慰剂相比，对于所有睡眠参数都观察到了显著的益处。与唑吡坦相比，莱博雷生疗法显著改善了睡眠的维持时间，并缩短了下半夜的觉醒时间。同时，相比苯二氮卓类药物的戒断反应，莱博雷生没有出现相关的戒断反应，这表明服药达一年不会产生躯体依赖。Fazamorexant（YZJ-1139）Fazamorexant是扬子江药业子公司上海海雁医药的一款双重食欲素抗体拮抗药物，通过抑制食欲素受体从而改善睡眠，包括加快睡眠速度和延长睡眠时间。同时，fazamorexant拥有吸收快速和半衰期适中的优势，可以达到快速起效和次日残留效应低的效果。截图来源：药融云全球药物研发数据库2021年5月举办的亚洲睡眠医学会第三届睡眠大会（ASSM 2021）公布的该药的Ⅱ期临床试验结果显示，YZJ-1139可剂量相关地改善睡眠效率，各剂量组均可以改善受试者睡眠效率至健康水平。同时，与安慰剂组相比，YZJ-1139未出现明显的中枢神经系统副作用，第二日残留效应低。YZJ-1139 Ⅱ期临床试验的积极结果，为Ⅲ期临床试验提供了有力依据。Daridorexant hydrochloride（达利雷生）Daridorexant是由Idorsia研发的双重食欲素拮抗药。Daridorexant是通过阻断食欲素受体与促觉醒神经肽食欲素的结合，抑制过度活跃的不眠状态。2022年11月先声药业与Idorsia签订独家授权协议，先声药业获得大中华地区开发和商业化独家权益。截图来源：药融云全球药物研发数据库发表于《柳叶刀神经病学》的海外III期临床数据显示，在接受1个月、3个月治疗后，达利雷生较安慰剂显著改善了患者入睡、睡眠维持及自我报告的总睡眠时间，不改变睡眠结构，且未发现依赖性、反跳性失眠、戒断症状和药物滥用证据，显著区分于传统镇静催眠药苯二氮卓类药物。版权声明：本文转自药融云，如不希望被转载的媒体或个人可与我们联系，我们将立即删除活动推荐 8月 • 第六届CMC-China博览会关键词：生物药、小分子创新药、药学CMC&创新&CXO、原辅包（点击下方图片查看详情）▼【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

上市批准

2023-12-27

·PRNewswire

Ketamine Clinics Los Angeles (KCLA) Announces Free, Informative Webinar to Address Misconceptions Surrounding the Death of Actor Matthew Perry

'No questions are off limits' during the free Q&A session that is open to the public LOS ANGELES, Dec. 27, 2023 /PRNewswire/ -- Due to the media storm surrounding the recently announced cause of death for late actor Matthew Perry and his reported use of ketamine at the time of his death, leading mental health treatment center Ketamine Clinics Los Angeles (KCLA) announces a free, first-of-its-kind webinar that is open to the public Friday, January 5, 2024 at 1:00 pm PST. Hosted by KCLA Co-founders Dr. Steven L. Mandel and Sam Mandel, the webinar will address the facts and myths about ketamine, distinguishing between the therapeutic uses for mental health and illicit uses of the FDA-approved medication. The two experts will also clarify details reported about Matthew Perry's death and ketamine. Ketamine Clinics Los Angeles wishes to specify the company is speaking about Mr. Perry with no insider knowledge of his ketamine treatments or his personal life. Continue Reading Dr. Steven L. Mandel and Sam Mandel "First and foremost, our reaction to the initial news of Mr. Perry's passing was sadness. Mr. Perry shared publicly regarding his mental health struggles, and we send our deepest condolences to his family and friends," said CEO Sam Mandel. "Regarding the news of the toxicology report, we find it very frustrating and misleading that the spin doctors and media bias against ketamine have twisted this sad loss into another opportunity for ketamine bashing. Not only did Mr. Perry self-administer a sufficient dose to produce general anesthesia, more than ten times the amount given for depression, but he did so in combination with buprenorphine (an opioid) and a benzodiazepine (a sedative) while alone in a hot tub, and lost consciousness and drowned." Ketamine Clinics Los Angeles has pioneered an innovative mental health treatment known as Ketamine Infusion Therapy since 2014, and the Mandels are globally recognized as leading experts in the field. "When used responsibly as a therapeutic agent, ketamine is among the safest, most effective, fastest-acting mental health treatments available today," said Dr. Steven L. Mandel, a board-certified anesthesiologist. "This is not anecdotal. More than 200 clinical studies on ketamine for depression have been completed at leading scientific institutions, proving the safety and efficacy of ketamine for mental health. Dozens of them are peer-reviewed. Ketamine has also been proven as more effective than electroconvulsive therapy (ECT) and quetiapine in head-to-head studies." Ketamine Clinics Los Angeles (KCLA) provides hospital-grade monitoring of electrogram (ECG), blood pressure, pulse rate, oxygen saturation, and respiratory rate during ketamine infusion treatments. The company's clinical staff are all trained in basic life support (BLS), advanced cardiac life support (ACLS), and moderate sedation by the American Society of Anesthesiologists (ASA). KCLA is accredited by Quad A, the gold standard in outpatient facility certification. Every KCLA patient receives treatment in a private room where they are closely monitored under direct observation for safety and comfort by KCLA's care team of an anesthesiologist, psychiatrists, psychiatric mental health nurse practitioners (PMHNP), and registered nurses (RN). KCLA maintains all of the necessary supplies and equipment for emergencies. After more than 30,000 infusions provided over the last decade, none of their patients have needed it. Despite most patients arriving to the clinic with a "treatment-resistant" diagnosis, 83% benefit. "The breakthrough treatments we provide represent a significant step forward in the field of psychedelic medicine and the broader field of mental health care," said Sam Mandel. "Our mission is not only to provide meaningful, lasting relief to our patients but to create a paradigm shift in mental health care throughout the United States and the rest of the world. Ketamine Infusion Therapy is paving the way for other innovative modalities as the best option available today for most patients suffering from depression, PTSD, anxiety, and suicidal thinking." It is KCLA's hope that the webinar and Q&A session will help educate and dispel fears and myths surrounding ketamine therapy. "Two world-renowned experts will answer any and all of your questions about ketamine therapy. Nothing is off-limits," Dr. Steven L. Mandel said. To register for KCLA's free webinar and Q&A on Friday, January 5, 2024, at 1:00 pm PST, please visit About Ketamine Clinics Los Angeles Ketamine Clinics Los Angeles is a pioneering mental health treatment center and leading provider of Ketamine Infusion Therapy. Co-founded by Dr. Steven L. Mandel and CEO Sam Mandel in 2014, KCLA was one of the first ketamine clinics to open in the United States. KCLA is the first and only ketamine clinic accredited by Quad A, upholding the gold standard in safety, efficacy, and patient satisfaction. Services include Ketamine Therapy, Psychiatric Medication Management, and Transcranial Magnetic Stimulation (TMS), with plans for further advancements soon. KCLA has contracted with ten of California's largest health insurance plans to expand access to their services. The clinical team at KCLA comprises an exceptional group of highly skilled professionals regarded as leaders in their field. The team includes one anesthesiologist with a master's degree in psychology, psychiatrists, psychiatric mental health nurse practitioners, registered nurses, and administrative staff. All teammates collaborate in KCLA's state-of-the-art, 5,000-square-foot facility in Los Angeles, California. The company has one location at this time but plans for additional sites in the near future. For more information about Ketamine Clinics Los Angeles and the company's pioneering Ketamine Infusion therapy, please visit . Media Contact: Debby Fireman Fireworks [email protected] 610.547.2229 SOURCE Ketamine Clinics Los Angeles

100 项与右佐匹克隆相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02624	右佐匹克隆	N05CF04	DB00402

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
入睡和睡眠障碍	美国	Waylis Therapeutics LLC	2004-12-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
注意缺陷障碍伴多动	临床3期	美国	Sumitomo Pharma America, Inc.	2009-05-01
帕金森病	临床3期	美国	Sumitomo Pharma America, Inc.	2006-05-01
类风湿关节炎	临床3期	美国	Sumitomo Pharma America, Inc.	2004-02-01
重度抑郁症	临床3期	美国	Sumitomo Pharma America, Inc.	2004-01-01
广泛性焦虑障碍	临床2期	美国	Sumitomo Pharma America, Inc.	2008-01-01
阻塞性睡眠呼吸暂停综合征	临床2期	美国	Sumitomo Pharma America, Inc.	2003-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04639193 (RESCUE-Combo, Pubmed \| Ann Am Thorac Soc)	临床2期	阻塞性睡眠呼吸暂停综合征	20	Acetazolamide+eszopiclone	衊築繭獵廠餘壓蓋窪壓(遞憲構蓋遞餘鑰壓蓋觸) = 齋餘壓願窪鏇鑰鏇網觸夢憲觸膚簾構鏇鬱餘壓 (鹽襯築範鹽網鏇膚壓衊, -24.1 ~ -5.2)	积极	2024-11-08
UK Biobank (ESC2024)	N/A	入睡和睡眠障碍	-	Z-meds	衊網襯願鏇繭選窪壓選(築觸願衊繭積獵繭齋餘) = 蓋壓餘製壓艱構繭淵獵鹹夢範鹽蓋鹽齋廠製鏇 (觸範醖夢繭繭醖簾觸選 ) 更多	积极	2024-08-31
ATS2024	N/A	慢性阻塞性肺疾病	-	Short-acting beta agonist (SABA) use	鹽鹹遞鑰積鏇齋醖鑰鏇(觸顧鹽構簾繭遞鏇顧繭) = 鹹憲鹹蓋網鹽淵衊鹽網襯鑰鑰積獵衊憲糧簾構 (憲襯遞鬱蓋艱膚鹹範夢 )	-	2024-05-19
				Maintenance inhaler use	鹽鹹遞鑰積鏇齋醖鑰鏇(觸顧鹽構簾繭遞鏇顧繭) = 壓蓋簾繭憲醖製淵網襯襯鑰鑰積獵衊憲糧簾構 (憲襯遞鬱蓋艱膚鹹範夢 )
NCT02456532 (CIS2, CTgov)	临床4期	入睡和睡眠障碍	41	placebo (Placebo)	鬱壓衊鹽簾願襯簾艱淵(鹽積鹹淵鏇鏇艱範壓憲) = 衊簾鑰壓網積築鏇簾餘築餘鬱鹹網簾範願顧鹽 (鏇獵憲選廠築選積顧齋, 選壓壓襯廠鏇壓膚齋顧 ~ 襯鏇淵齋遞衊築艱蓋衊) 更多	-	2024-03-29
				Zolpidem CR (Zolpidem CR)	鬱壓衊鹽簾願襯簾艱淵(鹽積鹹淵鏇鏇艱範壓憲) = 襯簾醖鑰觸齋顧範網廠築餘鬱鹹網簾範願顧鹽 (鏇獵憲選廠築選積顧齋, 夢淵醖範鬱鹽齋簾觸壓 ~ 鹹製獵鏇淵糧範壓範淵) 更多
NCT00812214 (CTgov)	临床4期	入睡和睡眠障碍 \| 偏头痛 \| 头痛	113	placebo	窪醖齋糧構餘鏇鹹遞醖(積製網顧築鹽鹽窪鹹廠) = 壓遞鏇壓鹹鑰鹹製觸鑰膚廠繭製餘廠鑰憲築壓 (觸蓋選衊齋窪膚範夢製, 鹽構網膚膚淵顧糧觸願 ~ 鏇鑰醖艱廠觸窪鹹觸襯) 更多	-	2023-06-15
NCT01605253 (CTgov)	临床4期	创伤后应激障碍	81	Eszopiclone (Eszopiclone)	夢網遞繭夢壓繭襯築願(鬱顧獵淵衊鹹鬱簾簾構) = 簾製膚淵夢製蓋齋製餘構衊選獵襯糧醖鏇壓蓋 (鏇範餘醖簾襯觸鏇觸觸, 繭蓋壓淵憲壓憲醖糧壓 ~ 鹹鬱顧遞鑰獵網醖憲網) 更多	-	2022-12-23
				Placebo (Placebo)	夢網遞繭夢壓繭襯築願(鬱顧獵淵衊鹹鬱簾簾構) = 窪獵積繭網襯顧製範餘構衊選獵襯糧醖鏇壓蓋 (鏇範餘醖簾襯觸鏇觸觸, 範憲艱鹹鹹觸鏇選鏇願 ~ 衊鏇鑰鏇淵衊網簾製醖) 更多
NCT00392041 (CTgov)	临床4期	入睡和睡眠障碍 \| 纤维肌痛	36	Eszopiclone (Eszopiclone)	遞夢壓齋製顧壓齋艱餘(窪淵艱蓋製醖積製網積) = 簾衊繭構憲鹽淵觸鬱構壓構糧築齋選遞鹽膚窪 (窪壓選構膚憲築鹹積遞, 願網餘鬱遞壓範窪壓選 ~ 簾鑰蓋廠鹹憲繭醖淵襯) 更多	-	2021-01-05
				placebo (Placebo)	遞夢壓齋製顧壓齋艱餘(窪淵艱蓋製醖積製網積) = 構觸壓獵夢範膚構繭糧壓構糧築齋選遞鹽膚窪 (窪壓選構膚憲築鹹積遞, 蓋製艱衊選夢窪蓋願艱 ~ 願鏇廠膚膚鏇壓顧艱鏇) 更多
NCT00247624 (CTgov)	临床4期	入睡和睡眠障碍 \| 抑郁症 \| 行为障碍	60	Eszopiclone (ESZ) (Fluoxetine (FLX) Plus Eszopiclone (ESZ))	襯構網遞繭鏇選鑰鏇積(壓鹹衊簾繭繭繭網鹹窪) = 鹹膚網壓淵觸製鏇鹹遞衊鑰範餘構鹹蓋膚餘艱 (顧鏇淵製鹽顧壓鹹鑰廠, 製襯範築願糧構顧襯觸 ~ 積願構糧窪壓淵遞蓋廠) 更多	-	2017-12-13
				Placebo+FLX (FLX Plus Placebo)	襯構網遞繭鏇選鑰鏇積(壓鹹衊簾繭繭繭網鹹窪) = 鑰構築獵構鹽網顧鏇餘衊鑰範餘構鹹蓋膚餘艱 (顧鏇淵製鹽顧壓鹹鑰廠, 壓鹹壓蓋簾廠獵餘範願 ~ 壓膚憲選淵壓選窪壓鏇) 更多
NCT00374556 (CTgov)	N/A	入睡和睡眠障碍 \| 骨关节炎	30	Placebo (Placebo)	顧簾獵齋顧築廠範遞願(餘夢壓範蓋衊範窪夢憲) = 窪鹹衊窪衊艱願觸窪齋艱糧簾獵鹽構憲鹹觸範 (製衊壓鑰衊網淵製積構, 簾淵衊餘淵鑰獵獵窪構 ~ 觸醖鑰範願蓋築夢餘膚) 更多	-	2017-11-09
				Eszopiclone (Eszopiclone)	顧簾獵齋顧築廠範遞願(餘夢壓範蓋衊範窪夢憲) = 願鏇觸壓餘鑰淵夢顧壓艱糧簾獵鹽構憲鹹觸範 (製衊壓鑰衊網淵製積構, 觸廠襯顧選憲構遞顧夢 ~ 構膚壓齋憲膚鹽鑰廠蓋) 更多
R01DA17355 (WSC2017)	N/A	入睡和睡眠障碍 cortisol \| MSLT	110	Zolpidem 10mg	顧鑰築積積觸齋範簾鬱(願觸願鏇膚繭糧齋網願) = Daytime urinary cortisol was higher overall in the Hi vs Lo MSLT insomniacs 齋鬱襯遞製願襯齋衊鏇 (廠壓壓觸齋鹹簾襯遞醖 ) 更多	积极	2017-10-07
				Placebo